Actively Recruiting

All Genders
ID06819410

A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease

Led by Sichuan Provincial People's Hospital · Updated on 2025-02-11

1000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to evaluate the effectiveness and safety of two types of antifungal drugs, amphotericin B and azoles, in patients with invasive fungal disease. The study collects medical records, demographic details, and clinical data from patients treated at Sichuan Provincial People's Hospital between 2021 and 2024 to compare these treatments. The purpose is to better understand how these drugs perform in real clinical settings to inform future care. Patients receive treatment with either polyene antifungal drugs, such as amphotericin B or its cholesteryl sulphate complex, or azole antifungal drugs, including triazoles or imidazoles. The dosage and length of treatment for both drug types are determined by clinicians based on clinical practice. The study is observational, recording outcomes as patients undergo their prescribed treatments. Participants contribute by allowing access to their medical records and clinical data for analysis. Researchers assess the clinical success rate at the end of treatment and up to one year afterward. Safety is monitored during treatment, at day 14, and at day 28 after treatment starts. The study does not involve additional interventions or procedures, focusing on data collection and evaluation over several months.

CONDITIONS

Brief Title

Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • There is no age limit, gender is not limited
  • Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for  7 days
Not Eligible

You will not qualify if you...

  • Patients with incomplete data or other factors affecting the clinical outcome judgement
  • Patients who are judged by the investigator to be unsuitable to participate in this study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Retrospective collection of medical records from 2021 to 2024

Treatment

Duration - At least 7 days

Participants receive treatment with either amphotericin B or azole antifungal drugs as determined by their clinicians.

Treatment duration varies per clinical practice, monitored up to 14 days with safety assessments

Follow-up

Duration - Up to 1 year

Participants are observed for safety and clinical success up to 1 year after treatment.

Safety assessments during treatment and at Day 28; clinical success evaluated at the end of treatment up to 1 year

Trial Site Locations

Total: 1 location

1

Sichuan Provincial People's Hospital

Chengdu, Sichuan, China, 610072

Actively Recruiting

Loading map...

Research Team

L

lingai Pan, PhD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

FungiScope - A Global Emerging Fungal Infection Registry

Invasive Fungal Disease

Actively Recruiting

1 location

Immunomonitoring of Mold Invasive Infections

Invasive Fungal Disease

Actively Recruiting

1 location

Efficacy and Safety of Liposomal Amphotericin B and Isavucon...

Invasive Fungal Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here